Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphoma.

Simple item page
dc.creatorLueza, Béranger
dc.creatorAupérin, Anne
dc.creatorRigaud, Charlotte
dc.creatorGross, Thomas G
dc.creatorPillon, Marta
dc.creatorDelgado, Rafael F
dc.creatorUyttebroeck, Anne
dc.creatorAmos Burke, GA
dc.creatorZsíros, József
dc.creatorCsóka, Monika
dc.creatorSimonin, Mathieu
dc.creatorPatte, Catherine
dc.creatorMinard-Colin, Véronique
dc.creatorBonastre, Julia
dc.date2024-02-12T18:20:38Z
dc.date2024-03
dc.date2022-04-15
dc.date2024-02-12T18:20:37Z
dc.date.accessioned2026-08-03T04:15:29Z
dc.descriptionAcknowledgements: We would like to thank Gisèle Goma and Anthony Mangin for the data management for the patients at the EICNHL sites; Muriel Wartelle for IT coordination. The authors thank Yuki Takahashi for editing.
dc.descriptionFunder: Ministère des Affaires Sociales, de la Santé et des Droits des Femmes; doi: http://dx.doi.org/10.13039/501100006022
dc.descriptionOBJECTIVES: The randomized controlled trial Inter-B-NHL ritux 2010 showed overall survival (OS) benefit and event-free survival (EFS) benefit with the addition of rituximab to standard Lymphomes Malins B (LMB) chemotherapy in children and adolescents with high-risk, mature B cell non-Hodgkin's lymphoma. Our aim was to assess the cost-effectiveness of rituximab-chemotherapy versus chemotherapy alone in the French setting. METHODS: We used a decision-analytic semi-Markov model with four health states and 1-month cycles. Resource use was prospectively collected in the Inter-B-NHL ritux 2010 trial (NCT01516580). Transition probabilities were assessed from patient-level data from the trial (n = 328). In the base case analysis, direct medical costs from the French National Insurance Scheme and life-years (LYs) were computed in both arms over a 3-year time horizon. Incremental net monetary benefit and cost-effectiveness acceptability curve were computed through a probabilistic sensitivity analysis. Deterministic sensitivity analysis and several sensitivity analyses on key assumptions were also conducted, including one exploratory analysis with quality-adjusted life years as the health outcome. RESULTS: OS and EFS benefits shown in the Inter-B-NHL ritux 2010 trial translated into the model by rituximab-chemotherapy being the most effective and also the least expensive strategy over the chemotherapy strategy. The mean difference in LYs between arms was 0.13 [95% CI 0.02; 0.25], and the mean cost difference € - 3 710 [95% CI € - 17,877; € 10,525] in favor of rituximab-chemotherapy group. For a € 50,000 per LY willingness-to-pay threshold, the probability of the rituximab-chemotherapy strategy being cost-effective was 91.1%. All sensitivity analyses confirmed these findings. CONCLUSION: Adding rituximab to LMB chemotherapy in children and adolescents with high-risk mature B-cell non-Hodgkin's lymphoma is highly cost-effective in France. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01516580.
dc.formatapplication/pdf
dc.formatapplication/zip
dc.formattext/xml
dc.identifier1618-7598
dc.identifiers10198-023-01581-y
dc.identifier1581
dc.identifierhttps://www.repository.cam.ac.uk/handle/1810/364479
dc.identifier1618-7601
dc.identifier.urihttps://repo.dare.co.zw/handle/123456789/186987
dc.languageen
dc.languageeng
dc.publisherSpringer Nature
dc.publisherhttps://doi.org/10.1007/s10198-023-01581-y
dc.subjectEconomic evaluation
dc.subjectHigh-risk B-NHL
dc.subjectImmunotherapy
dc.subjectSemi-Markov model
dc.subjectChild
dc.subjectHumans
dc.subjectAdolescent
dc.subjectRituximab
dc.subjectCost-Effectiveness Analysis
dc.subjectCost-Benefit Analysis
dc.subjectProgression-Free Survival
dc.subjectLymphoma, Non-Hodgkin
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.titleCost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin's lymphoma.
dc.typeArticle

Files

Collections

University of Cambridge Apollo